CTRI/2012/10/003064已完成3 期
A Randomized, Double-Blind, Placebo-Control Study to Evaluate Efficacy and Safety of a Novel Enoki Mushroom (Flammulina Velutipes Sing, Chitoglucan Extract) on Weight Management in Healthy Volunteers
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Change from the baseline to the end of the treatment period in body weight, BMI, Wasit Hip Ratio
研究概览
简要总结
The study under trial is to investigate the efficacy of enokitake mushroom (chitoglucan extract) in providing a solution to a problem of increasing body weight to the over-weight subjects. Chitoglucan is a plant extract of edible enokitake mushroom (Flammulina velutipes Sing) containing natural therapeutic components (vegetal chitosan, beta-glucan and fatty acid complex). Chitoglucan has an anti-obesity property that is believed to be based on two of its natural components. chitoglucan is a safe and effective means of decreasing body fat and cardiovascular disease risk factors at a much lower dosage than regular crustacean-derived chitosan. The purpose of this study is to assess the clinical effectiveness of chitoglucan extracted from edible enokitake mushrooms versus placebo in over-weight subjects whose BMI falls within the range of 26-32. Enrolled subjects will receive chitoglucan or a placebo as Study medication.
研究设计
- 研究类型
- Interventional
- 分配方式
- Permuted block randomization, fixed
- 盲法
- Participant, Investigator and Outcome Assessor Blinded
入排标准
- 年龄范围
- 21.00 Year(s) 至 45.00 Year(s)（—）
- 性别
- All
入选标准
- •1 Male or female subjects between 21 to 45 years of age.
- •2 Subject with BMI range (26-32).
- •3 Ability to understand the risks/benefits of the protocol.
- •4 Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera ®, or double-barrier and have a negative pregnancy test at the Screening Visit.
- •Female subjects of non childbearing potential must be amenorrheic for at least 1 years or had a hysterectomy and/or bilateral oophorectomy.
- •5 Willingness to participate in a walking-exercise program (5 days a week, 30 min per day) with the scheduled timing per week during the course of the study 6 Subject agrees to consume a vegetarian/non-vegetarian diet of approximately 2,000 kcal/day (17% protein, 25% Fat and 58% carbohydrate) Subject should be available for duration of study period (6-8 months) 7 Subject using other therapies for weight management including physiotherapy/ occupational therapy agrees to discontinue these therapies during this study 8 Subject agrees not to start any new therapies for weight loss during the course of the study 9 Subjects agree to maintain the activity dairy 10 Willing to give written informed consent and willing to comply with trial protocol.
排除标准
- •1 Subjects suffered from intractable obesity, had defined weight limits or had experienced any recent, unexplained weight loss or gain 2 Subjects having history of underlying inflammatory arthropathy, septic arthritis, inflammatory joint disease, gout, pseudogout, Pagets disease, joint fracture, acromegaly, fibromyalgia, Wilsons disease, ochronosi, haemochromatosis, heritable arthritic disorder or collagen gene mutations or rheumatoid arthritis 3 Subjects having history of asthma 4 Subjects having history of cardiovascular diseases 5 Subjects having history of diabetes (Type I or Type II) except other than the subject having the pre-diabetes condition with the fasting blood glucose between 100 to 125 mg/dl or random blood glucose ≥ 140-199 mg/dl.
- •6 Subject with hyperuricemia (males 480 µmol/L, females 450 µmol/L) 7 Subjects having thyroid disease 8 Subjects having abnormal liver or kidney function test (ALT or AST 2 times the upper limit of normal; elevated creatinine, male 125 µmol/L, female 110 µmol/L) 9 Subjects having abnormal findings on complete blood count 10 Subjects having history of coagulopathies 11 Subjects with hypertension 12 Subjects with HIV Positive 13 Subjects having history of congestive heart failure 14 Subjects having history high alcohol intake (2 standard drinks per day) 15 Pregnant, breast feeding or planning to become pregnant during the study 16 Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent 17 Any other condition that, in the opinion of the investigator, would adversely affect the subjects ability to complete the study or its measures 18 Subjects participated in any investigational study medication within thirty (30) days prior to screening.
结局指标
主要结局
Change from the baseline to the end of the treatment period in body weight, BMI, Wasit Hip Ratio
时间窗: Day 0 Day 15 Day 30 Day 60 Day 90 and Day 120
次要结局
- Change from the baseline to the end of the treatment period in Visual Analog Scale (VAS) and Profile of Mood States-Short Form (POMS-SF) questionnaire.(Body-fat composition analysis by DEXA)
- Change from the baseline to the end of the treatment period in LDL, HDL, VLDL, triglycerides, total cholesterol(Day 0 Day 30 Day 60 and Day 120)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
Effects of a Mushroom Blend on Gastrointestinal Symptoms and the MicrobiomeNCT07027462University of South Carolina40
尚未招募
不适用
Clinical Study of De-Stress & Happy Gut Powder for Stress and Indigestion in Adults.StressIndigestionDyspepsiaNCT06568965Herbolab India Pvt. Ltd.81
尚未招募
不适用
A Clinical Study of De-Stress & Chill Gummies in Reducing StressStressAnxietyNCT06571071Herbolab India Pvt. Ltd.72
已完成
4 期
Statin Therapy in Heart Failure: Potential Mechanisms of BenefitHeart Failure, CongestiveNCT00233480University of California, Los Angeles27
已完成
1 期
A Study of CDX-0159 in Patients With Prurigo NodularisPrurigo NodularisNCT04944862Celldex Therapeutics24